ResMed develops cloud-connected medical devices and digital health software for treating and managing chronic diseases including sleep apnea, COPD, and respiratory conditions. Founded in Australia in 1989, the company has grown to over 10,000 employees and operates across more than 140 countries. Its product portfolio spans three primary segments: cloud-connected CPAP and sleep apnea systems, bilevel devices and ventilators for respiratory care, and out-of-hospital healthcare management software platforms.
The company's technology infrastructure centres on remote patient monitoring and chronic disease management capabilities built into cloud-connected devices and digital platforms. These systems enable healthcare professionals and caregivers to manage patients outside traditional hospital settings, shifting care delivery toward home and residential environments. ResMed's offerings include devices, masks, accessories, and integrated digital health solutions designed to support both patients and the professionals managing their care.
ResMed has impacted over 154 million lives in the past 12 months through its device and software platforms. The company operates with an explicit mission to change 500 million lives by 2030, reflecting its strategic focus on expanding access to digital health technologies and enabling people to manage chronic conditions with greater independence and quality of life.
